AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris
AstraZeneca says its add-on pill for a rare blood disorder known as paroxysmal nocturnal hemoglobinuria, or PNH, helped patients already taking Ultomiris or Soliris produce …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.